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Abstract
Limited information exists about epidemiology and risk factors of infection following pancreas-kidney transplantation and its impact on
long-term pancreatic graft function. A retrospective chart review of episodes of severe infection in consecutive pancreas-kidney
transplantations in a single institution was performed to assess the epidemiology, risk factors for infection and their impact on the
development of pancreatic graft dysfunction. Ninety-four (81%) of 116 recipients (median follow-up of 1492 days; mean 1594) developed
248 episodes of severe infection. Bacterial infections were present in 208 episodes, with 12% of the isolates resistant to antibiotics used in
prophylaxis. There were 40 episodes of fungal infection in 32 patients (28%) (mostly Candida spp), and CMV disease appeared in 20 patients
(17%), of which 50% appeared after the third month following surgery. The multivariate analysis identiﬁed that surgical re-intervention and
the use of steroid pulses were independently associated with the development of any infection. Additionally, pre-transplant evidence of
peripheral artery disease, a longer cold ischaemia time and high transfusional requirements were associated with fungal infections.
Cytomegalovirus (CMV) mismatch was independently related to CMV disease and female sex, and bladder drainage of the exocrine
pancreas was associated with urinary tract infection. At the end of follow-up, 29 patients (25%) had developed severe pancreatic graft
dysfunction, and fungal infection was independently associated with it. Our study identiﬁes a subset of pancreas-kidney transplant recipients
at a higher risk of developing severe infection. Fungal infection is an independent risk factor for the development of severe pancreatic graft
dysfunction.
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Introduction
Combined pancreas and kidney transplantation (PKT) is now
considered to be an accepted therapeutic option for
patients with diabetes and end-stage renal failure [1,2].
The increasing success of pancreas transplantation is the
result of better surgical techniques, immunosuppressive
therapies, and the rational use of antimicrobials [3].
However, and despite such advances, infection remains a
major cause of morbidity and mortality after PKT, increasing
costs and having a negative impact on graft and patient
survival [4–6].
In contrast to what occurs with other types of transplants,
information regarding infectious complications following pan-
creas transplantation is scant and controversial. Most
published studies have focused on speciﬁc types of infections
or short-term infectious complications, but comprehensive
reports involving enough recipients with an adequate
follow-up are scarce [7]. As a consequence, there is not
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an infection-related standard of care following pancreas
transplantation, and important questions remain to be
answered regarding the impact of infection on this type of
transplant.
The aim of our study was to describe the epidemiology and
microbiological characteristics of severe infections following
PKT, as well as to analyse the risk factors associated with
infection and its impact on long-term pancreatic graft function.
Material and Methods
Study population
We performed a retrospective chart review of the entire
cohort of consecutive patients who underwent pancreatic
transplantation in our institution from March 1995 to Septem-
ber 2008. We excluded patients who underwent pancreas
transplantation as a part of a multivisceral transplant (with the
exception of kidney transplants). All patients were followed-up
to April 2010 or until they died or lost the pancreatic graft. The
local ethical committee approved the study.
Variables related to donors and recipients were extensively
reviewed. Recipient characteristics included: age, sex, type of
diabetes, time from diabetes diagnosis, Charlson index [8],
evidence of peripheral artery disease (PAD), type of pre-trans-
plant dialysis, time on dialysis and previous transplant. Pre-trans-
plantation variables included body mass index (BMI),
biochemical and haematological data within 24 hours prior to
transplant, including viral serologies, and crossmatching for HLA
compatibility. Donor characteristics were also recorded,
including age, sex, vasoactive drug requirements, BMI and
CMV serostatus. Intraoperative factors included length of
transplant surgery, cold and warm graft ischaemia time, blood
product units given during surgery, and type of pancreatic
exocrine drainage. Additionally, postoperative factors were
analysed, including length of intensive care unit stay, vascular
amine requirements, surgical re-intervention, immunosuppres-
sive treatment, need for dialysis, acute or chronic rejection and
length of hospital stay during the ﬁrst hospitalization. The
following outcomeswere noted: duration of follow-up, pancreas
graft survival, tumours and mortality at the end of follow-up.
Data about microbiology, timing and site of each episode of
infection were also collected.
Surgical technique
Pancreas transplantation was performed following standard
techniques, as described previously [9]. Drainage of the
exocrine pancreatic secretions was carried out using bladder
drainage (mostly during the ﬁrst years of the study) or enteric
drainage.
Immunosuppression
Induction immunosuppression therapy included quadruple
therapy with antithymocyte globulin (ATG) induction
(1.5 mg/kg/day; range, 6–12 days), tacrolimus azathioprine or
mycophenolate mofetil, and steroids. Those patients with
allergic reactions to ATG received basiliximab. Acute rejection
episodes were treated with steroid pulses.
Antimicrobial prophylaxis
Donor duodenal patches were irrigated with a solution
including cefalotin and amphotericin B or ﬂuconazole, as
previously described [3]. All patients received perioperative
antibacterial prophylaxis with vancomicin and ceftazidime for
3 days after transplantation and thereafter ciproﬂoxacin and
ﬂuconazole 100 mg/daily until discharge or for a maximum of
42 days [7]. Cotrimoxazole (800/160 mg) thrice weekly
during the ﬁrst 6 months was used in prophylaxis against
Pneumocystis jirovecii. CMV prophylaxis changed over time. All
patients received intravenous ganciclovir (5 mg/kg/24 IV,
adjusted to renal function) while they were receiving ATG.
Additionally, CMV-seropositive recipients received one of the
following regimens: (i) no additional prophylaxis (from 1995
to April 1999); (ii) universal prophylaxis with oral ganciclovir
or valganciclovir, adjusted to renal function for the ﬁrst
12 weeks after transplantation (from May 1999 to September
2008, except from September 2002 to December 2004); or
(iii) preemptive therapy (PT) guided by weekly pp65
antigenaemia (from September 2002 to December 2004).
CMV-seronegative recipients who received a graft from a
seropositive donor received prophylaxis with ganciclovir or
valganciclovir during the ﬁrst 12 weeks after transplantation
[10].
Deﬁnitions
Severe infections were deﬁned as those that needed
systemic antibiotic therapy and required at least 24 hours
of hospital admission. Centers for Disease Control and
Prevention (CDC)/National Healthcare Safety Network
(NHSN) criteria for infection deﬁnitions were used [11].
Asymptomatic bacteriuria and asymptomatic episodes of
CMV viraemia were speciﬁcally excluded from the analysis.
CMV disease required the presence of clinical symptoms
with the demonstration of virus by means of virological or
pathological methods [12]. A vascular surgeon, by means of
Doppler studies, arteriography or computed tomogra-
phy-guided angiography before transplantation, diagnosed
peripheral artery disease. Severe pancreatic graft dysfunction
was deﬁned as the need for permanent insulin therapy at
the end of the follow-up.
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Statistical analysis
Categorical variables were expressed as absolute and relative
frequencies. Quantitative variables were expressed as the
mean and standard deviation (SD) or median and interquartile
range (IQR). Differences between means were analysed using
Student′s t-test or the Mann–Whitney U-test as appropriate.
Categorical variables were compared using the chi-squared
test or Fisher′s exact test. Crude and adjusted odds ratios
(ORs) were calculated by logistic regression. Those variables
with a statistical signiﬁcance Wald p <0.10 in the univariate
analysis were introduced in a multivariate model. Ultimately,
the selection of the ﬁnal model was carried out according to
the Mallows′ Cp criterion and the area under the receiver
operating characteristic curves (ROC AUC). An SPSS v.15.0
program (SPSS Inc., Chicago, IL, USA), the script AllSetsReg
Computer Program for SPSS [13] and EPIDAT v.3.0 were used
for statistical analysis. Differences were considered to be
signiﬁcant at p <0.05.
Results
Demographic and baseline characteristics
Overall, 124 pancreas transplants were performed during the
study period. Eight patients were excluded from the analysis
(six with multivisceral transplantation and two due to missing
data). So we ﬁnally analysed 116 pancreas-kidney transplants in
111 patients (109 simultaneous kidney-pancreas transplanta-
tions, and seven pancreas transplants in patients with previous
kidney transplantation). Mean/median follow-up was 1594 days
(743-2213) and 1492 days, respectively. Regarding the type of
exocrine drainage, 58 transplants were performed using
bladder drainage while in the remaining 58 the drainage was
enteric. The main characteristics of the patients are detailed in
Table 1.
Incidence, microbiology and clinical characteristics of
infections:
Overall, 248 infections occurred in ninety-four (81%) trans-
plant recipients, with 44 (38% of recipients) developing
recurrent infection. Recipients with recurrent infection had a
longer hospital stay than patients with single infection (22 vs.
30 days; p <0.001).
Incidence density, timing and source of infections are shown
in Fig. 1. Overall, incidence of bacterial and fungal infections
was greater during the ﬁrst month, while CMV disease was
more frequent between the ﬁrst and the third month following
transplantation. All types of infection were more frequent
early after surgery, with a sharp decrease at the end of the ﬁrst
month following transplantation. However, there was a second
peak of urinary tract infections (UTIs) in the period from the
third to the sixth month after surgery.
Microbiological ﬁndings are shown in Table 2. Bacteria
accounted for 208 episodes of infection. Urinary tract infection
was the most common type of bacterial infection, appearing in
42% of the patients, followed by surgical site infection, which
occurred in 38% of the recipients, and catheter-related
bloodstream infections, which accounted for 27 episodes of
bacterial infection. Polymicrobial infections occurred in 39
cases, mostly (35/39) related to surgical site infection. Resis-
tance to prophylactic antibiotics was present in 12% of
bacterial isolates. Sixteen episodes of C. difﬁcile-associated
diarrhoea were found in 15 patients (13%). Additionally, there
were two cases of tuberculosis.
Forty episodes of fungal infections occurred in 32 patients
(28%). Candida was isolated in 37 episodes, while Aspergillus
occurred in two and Mucor occurred in the remaining episode.
Surgical site infection was the most common type of fungal
infection (31 episodes) caused by Candida (30) and Aspergillus
(1), followed by urinary tract infection (4 episodes) caused by
Candida, three catheter-related candidaemia and two cases of
TABLE 1. Baseline characteristics and outcome of the 116
pancreas-kidney transplant recipients
Variable Finding
Age, mean years (SD)
Donor 27  18
Recipient 38  13
Sex (male), n (%)
Donor 79/116 (68%)
Recipient 68/116 (59%)
Mean pre-transplant recipient BMI, kg/m2 (SD) 23 (4)
Mean pre-transplant donor BMI, kg/m2 (SD) 23 (3)
Median time from diagnosis of DM, years (IQR) 22 (18–26)
Median time on dialysis, months (IQR) 19 (13–28)
Previous haemodialysis, n (%) 72/116 (62%)
Previous peritoneal dialysis, n (%) 41/116 (35%)
Pre-transplant peripheral artery disease, n (%) 10/116 (9%)
CMV IgG + donor, n (%) 111/116 (96%)
CMV IgG + recipient, n (%) 79/116 (68%)
CMV mismatch (D+/R), n (%) 30/116 (26%)
EBV mismatch (D+/R), n (%) 2/116 (1.7%)
Mean basal albumin, g/dl (SD) 4 (0.6)
Mean basal leucocytes, No./ll (SD) 7424 (1908)
Type of exocrine drainage, n (%)
Enteric 58/116 (50%)
Bladder 58/116 (50%)
Mean cold ischaemia time, min (SD) 811  134
Induction immunosuppressive therapy, n (%)
Antithymocyte globulin 108/116 (93%)
Maintenance immunosuppressive therapy, n (%)
FK+AZA+ST 56/116 (48%)
FK+MMF+ST 60/116 (52%)
Steroid pulses, n (%) 26/116 (22%)
Post-transplant dialysis, n (%) 21/116 (18%)
Re-intervention, n (%) 43/116 (37%)
Allograft thrombosis, n (%) 25/116 (22%)
Median length of ﬁrst hospitalization, days (IQR) 25 (19–36)
Pancreas allograft chronic dysfunction, n (%) 29/116 (25%)
Global mortality, n (%) 6/116 (5%)
Infection-related mortality 3/116 (3%)
AZA, azathioprine; BMI, body mass index; CMV, cytomegalovirus; D+/R,
seropositive donor/seronegative recipient; FK, tacrolimus; IQR, interquartile
range; min, minutes; MMF, mycophenolate; n, number; SD, standard deviation; ST,
steroids.
Data are No./number tested (%) of patients, unless otherwise indicated.
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pulmonary fungal infection (Aspergillus and Mucor one case
each). In all cases of Candida-related surgical site infection,
fungi were isolated together with bacteria as a part of
polymicrobial ﬂora. Ten episodes of Candida infection (27%)
were caused by C. krusei or C. glabrata. No episode of
P. jirovecii pneumonia occurred during the follow-up.
CMV disease was diagnosed in 20 patients (17%). Primary
CMV disease occurred in 8/30 (27%) while 12 episodes of
CMV disease occurred among 79 seropositive recipients
(15%). Visceral CMV disease appeared in 11/20, and viral
syndrome in nine patients. No case of Epstein-Barr-related
post-transplant lymphoproliferative disorder was recorded
and no case of non-CMV viral infection required hospital-
ization.
Risk factors for infection
In Table 3 we show the results of the univariate and
multivariate analysis of risk factors associated with the
development of the different types of infection following
pancreas transplantation. The multivariate analysis identiﬁed
that surgical re-intervention and the use of steroid pulses were
associated with the development of infection. Additionally,
pre-transplant evidence of peripheral artery disease (PAD), a
longer cold ischaemia time and high transfusional requirements
were associated with the development of fungal infection.
Cytomegalovirus mismatch (donor seropositive/recipient
seronegative) was independently related to CMV disease and
female sex and bladder drainage of the exocrine pancreas were
associated with urinary tract infection.
(a) 
<1 month 1-3 months 3-6 months 6-12 months ≥1 year
Incidence density (events/1000 transplant-days)
Global infection 34.01 7.46 4.67 0.96 0.35
Bacterial infection 25.59 5.14 3.87 0.84 0.31
Fungal infection 8.11 0.83 0.34 0.06 0.03
CMV disease 0.31 1.49 0.8 0.06 0.01
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(b)
<1 month 1-3 months 3-6 months 6-12 months ≥1 year
Incidence density (events/1000 transplant-days)
Surgical site 12.17 2.32 0.34 0.22 0.05
Urinary tract infection 8.11 0.66 2.5 0.34 0.16
Catheter related 4.06 0.66 0.46 0.11 0.01
C. difficile diarrhoea 1.25 0.83 0.34 0.06 0.02
0
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FIG. 1. Timing and incidence density curves of severe infections following pancreas-kidney transplantation. (a) Major type of infectious
complications. (b) Source of infectious complications.
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Overall, exocrine bladder drainage was associated with a
higher incidence of infection than enteric drainage (incidence
density 1.3 vs 0.95/1000 transplant days; p 0.027) due to a
signiﬁcantly higher incidence of urinary tract infections (0.61 vs
0.28/1000 transplant days; p 0.001), while the incidence of
surgical site infection was similar.
Impact of infection on long-term pancreatic function and
mortality
At the end of follow-up, 29 patients (25%) had developed
severe pancreatic graft dysfunction. As is shown in Table 4,
fungal infection, acute rejection and graft thrombosis were
independently associated with severe graft dysfunction.
TABLE 2. Microbiology of severe infections following pancreas-kidney transplantation
Isolated microorganisms
Global (n = 269) SSI (n = 109) UTI (n = 83) CRBSI (n = 27)
n= % n= % n= % n %
Gram-positive bacteria 93 35 36 33 24 29 23 85
Negative-coagulase 33 35a 15 42 16 59
Staphylococcus aureus 9 10a 3 8 4 15
Enterococcus sp. 44 47a 18 50 22 92 3 11
Enterobacteriaceae 94 35 37b 34 48 58 1 4
ESBL-producing Enterobacteriaceae 10 11a
NFGNB 9 3 3 3 4 5 0 0
Candida sp. 40 15 32 29 5 6 3 11
C. glabrata or C. krusei 10 25a
Aspergillus sp. 2 1 1 1
Mucor sp. 1 1
Mycobacterium tuberculosis 2 1
Culture negative 13c 5 0 0
ESBL, extended-spectrum beta-lactamase; CRBSI, catheter-related bloodstream infection; MDR, multidrug resistant; MRSA, methicillin-resistant S. aureus; NFGNB, non-fermenting
gram-negative bacilli; SSI, surgical site infection; UTI, urinary tract infection.
Data are expressed in number of episodes (n) and percentage of total isolates (%).
aRelative frequencies for species and drug-resistant pathogens refer to total isolates in their category.
bIncludes anaerobes (15 Bacteroides sp.).
cThere were eight culture-negative respiratory infections.
Univariate analysis Multivariate analysis
OR 95% CI p OR 95% CI p
Any infection
Surgical-intervention 3.2 1.1–10.2 0.045 3.1 1.1–8.6 0.027
Steroid pulses 7.2 0.9–56.4 0.060 5.4 1.2–25.1 0.030
Pre-transplant
haemodialysis
2.0 0.8–5.2 0.139 –
Fungal infection
Peripheral artery disease 2.4 0.7–8.8 0.093 6.3 1.2–33.1 0.029
CIT (per minute)a 1.007 1.003–1.011 0.001 1.005 1.001–1.009 0.026
Transfusion requirement 3.1 1.3–7.4 0.011 3.5 1.2–9.9 0.017
Surgical re-intervention 2.6 1.2–5.9 0.020 –
Azathioprine use 3.0 1.3–6.8 0.009 –
Steroid pulses 2.4 0.96–5.8 0.062 4.2 1.4–12.6 0.010
CMV disease
CMV mismatch (D+/R) 2.2 0.8–6.2 0.118 4.0 1.2–13.5 0.025
Preemptive therapy‡ 1.7 0.5–5.9 0.421 –
No additional
prophylaxisb
3.6 0.8–16.7 0.108
Acute rejection 5.4 1.9–15.2 0.001 –
Steroid pulses 5.0 1.8–14.0 0.002 5.9 1.9–18.0 0.002
SSI
Peripheral artery disease 7.4 1.5–36.9 0.014 8.9 1.7–47.5 0.010
Thrombosis 2.3 0.9–5.6 0.084 1.4 0.5–3.7 0.542
Surgical re-intervention 3.7 1.7–8.3 0.001 4.1 1.7–9.8 0.001
Azathioprine use 2.5 1.1–5.8 0.034 1.2 0.5–2.8 0.661
UTI
Sex (male) 0.4 0.2–0.9 0.021 0.4 0.2–0.9 0.033
Enteric drainage 0.3 0.1–0.7 0.006 0.4 0.2–0.9 0.034
Acute rejection 3.0 1.2–7.5 0.021 –
Steroid pulses 2.6 1.1–6.4 0.036 2.8 1.1–7.1 0.033
CIT, cold ischaemia time; CMV, cytomegalovirus; SSI, surgical site infection; UTI, urinary tract infection.
aEqual to crude OR 1.5 (95% CI, 1.2–1.9) per each hour. Adjusted OR 1.3 (95% CI, 1.1–1.7) per each hour. D+/
R = pre-transplant donor seropositive, recipient seronegative to CMV.
bVersus continuous prophylaxis (12 weeks post-transplant).
TABLE 3. Risk factor analysis by
type of infectious complication
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Six patients (5.1%) died, three of them due to infection
(Pseudomonas pneumonia, Aspergillus necrotizing pancreatitis
and Enterobacter cloacae and Candida glabrata surgical site
infection).
Discussion
Our data show that infections are an important cause of
morbidity and the ﬁrst cause of mortality following pancreas
transplantation. Eighty per cent of our recipients experienced
at least one episode of severe infection. The reported
incidence of infection following pancreas transplantation
ranges from 7% up to 95% [14–18]. Our data are supported
by a comprehensive analysis of all types of infection, with clear
and widely accepted surveillance deﬁnitions, and a long-term
follow-up. Actually, Rostambeigi et al. [7] reported a 63%
incidence of severe infections, but they excluded all infections
that occurred during the ﬁrst hospitalization unless they
prolonged the initial stay for more than 2 weeks.
As expected, bacterial microorganisms were the most
common pathogens causing severe infection after PKT.
Overall, surgical site infection was the most frequent type of
bacterial infection in the ﬁrst 3 months after transplantation,
followed by urinary tract infection and catheter-related
bacteraemia. It is noteworthy that urinary tract infection was
the predominant type of infection from the third month after
transplant, mostly in patients in whom the exocrine drainage
was performed using the bladder.
Fungal and CMV disease accounted for a signiﬁcant part of
severe infections in this type of transplant. Fungal infection
(mainly Candida) occurred in 28% of our patients even with the
universal use of low-dose ﬂuconazole prophylaxis during the
ﬁrst weeks after surgery. Candida surgical site infection was the
most frequent type of fungal infection in this population, but in
all cases Candida was isolated together with bacteria as a part
of polymicrobial infection. Although the pathogenic role of
Candida in that setting could be controversial, there is no
doubt that most clinicians would agree to administer systemic
antifungal therapy upon the isolation of Candida in a clinical
sample in this type of patients. Moreover, fungal infection was
associated with graft dysfunction in the long-term follow-up,
and roughly one-quarter of the Candida infection episodes
were caused by C. glabrata or C. krusei. Further studies should
be undertaken to establish whether the use of higher doses of
ﬂuconazole or the administration of another type of antifungal
prophylactic agent such as other triazoles or echinocandins
might provide a better prevention of fungal infections after
pancreas transplantation.
Seventeen per cent of the recipients developed CMV
disease. This relatively high incidence of infection was probably
related to the use of ATG induction therapy. Actually, we have
previously shown that universal prophylaxis, but not preemp-
tive therapy, which was used during part of the study period, is
associated with a lower incidence of CMV disease in this type
of patient [10], and this recommendation is now widely
supported [19–21].
There is still some controversy about the inﬂuence of the
type of drainage on the development of infections after PKT
[9,22,23], as well as the role of pre-transplant peritoneal
dialysis as a risk factor for intra-abdominal infections
[22,24,25]. Our study conﬁrms that bladder drainage was
associated with a higher incidence of severe infection in
comparison with enteric drainage. In contrast, pre-transplant
use of peritoneal dialysis was not associated with an increased
risk of infection [7]. This is an important ﬁnding as this type of
dialysis is often used in diabetic patients.
Duration of transplantation surgery was not associated with
a signiﬁcantly higher risk of infection, but the multivariate
analysis identiﬁed the need for surgical re-intervention as an
important risk factor for developing infections, suggesting that,
as occurs in other transplant patients, total surgical time may
play an important role in the appearance of post-transplant
infections. Additionally, patients who receive steroid pulses,
those who have pre-transplant evidence of PAD, or
CMV-seronegative recipients who receive a graft from a
seropositive donor, form a subgroup of PKT recipients with a
higher risk of developing severe infections after surgery and
may need additional prophylactic measures.
Nonetheless, there are some drawbacks to our study.
This is a retrospective study and some facts that may
inﬂuence the appearance of infections may have changed
during the study period, including a possible ‘learning curve’
effect in the transplantation team and the impact of the type
of exocrine drainage, as bladder drainage was more often
TABLE 4. Impact of infection on long-term pancreatic func-
tion
Risk factors
Univariate analysis Multivariate analysis
OR 95% CI p OR 95% CI p
Any infection 2.4 0.7–8.9 0.182
Surgical site infection 3.8 1.6–9.3 0.003
Urinary tract infection 1.0 0.4–2.2 0.914
Fungal infection 4.4 1.8–10.9 0.001 8.4 1.9–37.0 0.005
CMV disease 1.4 0.5–3.9 0.571
Recipient BMI 1.0 0.9–1.1 0.464
Donor age 1.1 0.99–1.1 0.138
CMV mismatch (D+/R) 1.4 0.6–3.6 0.464
HCV infection 1.6 0.3–1.9 0.601
Acute rejection 3.2 1.2–8.2 0.016 15.6 2.8–86.9 0.002
Mycophenolate use 0,6 0.2–1–3 0.201
Allograft thrombosis 24.7 8.0–76.4 0.0005 142 21.3–955 0.0005
BMI, body mass index; CMV, cytomegalovirus; HCV, hepatitis C virus; D+/R,
pre-transplant donor seropositive/recipient seronegative to CMV.
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used at the beginning of the study period. However, we must
point out that the basic composition of the surgical and
infectious disease teams and immunosuppressive and antimi-
crobial therapy (with the exception of CMV prophylaxis)
have not been modiﬁed during the study period. On the
other hand, the design of the study makes it difﬁcult to
prove causality for some of the factors inﬂuencing long-term
pancreatic function.
In summary, severe infection is a major complication after
pancreas transplantation, with signiﬁcant effects in the short
and long-term follow-up. Our study identiﬁes a subset of
patients with a signiﬁcantly higher risk of developing severe
infections, and for whom standard preventive measures were
insufﬁcient. Prospective studies speciﬁcally carried out in this
high-risk population may clarify how to better prevent
infections, resulting in improved outcomes after PKT.
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